Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q1 2025 Earnings Presentation
21 slides from Expres2ion Biotech Holding Ab's earnings presentation, May 15, 2025
Slide 1: Interim Report
Interim Report Innovati vaccines healthiet world
Slide 2: Agenda
expreSeion BIOTECH Agenda * Strategic and Financial Review ES2B-C001: Breast Cancer Program Infectious Disease Programs Update * Q&A
Slide 3: Strategic and Financial
BIOTECH Strategic and Financial
Slide 4: Strategic Focus
Strategic Focus Key strategic areas for 2025 02 Actively drive and intensify collaborative initiatives in the development of vaccines 01 Advancing our proprietary pipeline University of Oxford — Malaria VICI Disease Consortium — Niexela} ES2B-C001 University of Copenhagen — Influenza (Mucosal delive
Slide 5: Development updates since Q4
expreSeion BIOTECH Strategic Focus Development updates since Q4 R&D Leadership Transition + Dr. Max Segaard promoted to CSO and Dr. Farshad Guirakhoo becomes Senior ES2B-CO001 Protoco! Amendment [May ‘25. AdaptVac mRNA Platform May '25 conjugates (ADCs) and expand study si Modular mRNA platform boos
Slide 6: Net sales and other operating income
Net sales Other operating income 1Q23 3Q23 1Q24 3Q24 1Q25 1Q23 3Q23 1Q24 3Q24 1Q25
Slide 7: Operating expenses
expreSeion O t . t BIOTECH SEK ‘000s Operating expense R&D costs (external) Personnel costs! ie} ie} ie} —— -10.000 -10.000 -10.000 ¥0,4% -20.000 -20.000 -20.000 -30.000 -30.000 -30.000 Volatile & dependent Reduced due to cost savings; upon pipeline activities sensitive to FX and inflation -40.000 -
Slide 8: Profit / loss for the period
expreSeion BIOTECH Profit / loss for the period SEK ‘000s 1Q profit / loss 10) -3.000 -6.000 -9.000 -12.000 _ -11.440 -12.853 -1% -15.000 2024 2025
Slide 9: Cash development in 2025
expreSeion BIOTECH Cash development in 2025 SEK millions 90,0 815 80,0 70,0 58,0 60,0 -20,3 a -3,2 50,0 40,0 30,0 20,0 10,0 0,0 December 2024 Operations FX March 2025
Slide 10: 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25
88 82 77 76 72 69 60 58 58 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25
Slide 11: ES2B-C001 Update
Slide 12: Phase I Design
expreSeion BIOTECH Phase | Design Open-label trial with ES2B-CO001 alone and combined with adjuvant * One site: Medical University of Vienna [currently under expansion] * Inclusion criteria: HER2-positive mBC patients, post 2nd line of treatment, ‘) zi! 7 i functioning immune system = = = = * Dose-e
Slide 13: Recruitment
expreScion BIOTECH Recruitment Steps taken to accelerate patient enrolment Protocol Enables combination with ADCs amendment filed Allows expansion of clinical trial sites to boost enrolment Targets Q3 2025 approval Vienna recruitment Agreements signed with five oncology clinics network Direct patien
Slide 14: Expected Timeline
Expected Timeline Schedule below assumes program moves directly to randomized POC Phase Il study. If a smaller Phase Il is chosen, initial costs will be lower but launch date later 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Phase | in Patients with Breast Cancer Phase II in Patients with Brea
Slide 15: 5
5
Slide 16: University of Oxford malaria vaccine candidates
University of Oxford malaria vaccine candidates expreSeion BIOTECH Vaccines in trial Trial abbreviation Phase Sites Trial status Estimated completion Pfs48/45 in Matrix-M VAC-085 | Oxford, UK Concluded March 2025, RHS.1 in BIO-002 la Sheffield, UK Fully recruited Q4.2025 Matrix-M VAC-089 la Oxford,
Slide 17: Update on other programs
Update on other programs Largely grant-sponsored and consortium driven Mucosal influenza vaccine with University of Copenhagen + Antigen production in S2 cell lines and glyco-modified cell lines + Initiated establishment of a Xylose cell line to support production of highly immunogenic antigens ea.
Slide 18: We Are a Platform-Based Vaccine Company
expreScion BIOTECH We Are a Platform-Based Vaccine Company We develop therapeutic vaccines (immunotherapy) against cancer as well as prophylactic vaccines against major infectious diseases Target Pre-clinical DISEASE Project/Target ID Identification Pharmacology _cGMP / Tox Phase Il Collaboration Pa
Slide 19: Looking forward
expreScion BIOTECH Looking forward Key value-driving milestones expected in 2025 and beyond NA Clinical & Pipeline Data ES2B-CO01: Recruitment — First patient first visit ES2B-CO0I: Safety/tolerability readout - Phase | dose escalation data incl. MTD ES2B-CO001: Immunogenicity & early efficacy signa
Slide 20: Q&A
Slide 21: Disclaimer
expreScion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the "Company"). Neither shall the presentati
ExpreS2ion Biotech Holding — Q1 2025 Earnings Presentation on 6ix